IL4 and diffuse scleroderma: Romilkimab, an anti-IL-4 and anti-IL-13 antibody (79, 80), has shown promising results in animal models and is currently undergoing Phase II trials (Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis, NCT02921971).